Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 387 (planned)
- Started
- Jan 23, 2019
- Main results expected
- Mar 30, 2033
- Fully finished
- Jun 16, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period
Measured over: Up to 28 days
Incidence and severity of treatment-emergent adverse events (TEAEs)
Measured over: Up to 5 years
Incidence and severity of adverse events of special interest (AESI)
Measured over: Up to 5 years
Assessment of the pharmacokinetics (PK) of linvoseltamab
Measured over: Up to 5 years
Concentrations of linvoseltamab in serum over time
Measured over: Up to 5 years
Objective response rate (ORR) as determined by an Independent Review Committee (IRC)
Measured over: Up to 5 years
Incidence and severity of cytokine release syndrome (CRS) with linvoseltamab
Measured over: Up to 5 years
ORR of IV linvoseltamab as assessed by investigator
Measured over: Up to 5 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03761108 · record last updated 2026-10-26 · checked 2026-11-09 15:47 UTC